1. Abou-Saleh MT. Lithium and bipolar illness. In: Montgomery S, Rouillon F, eds. Long-term treatment of depression. New York: John Wiley; 1992:113–138.

2. Akiskal HS, Haykal RF. Dysthymic and chronic depressive conditions. In: Georgotis A, Cancro R, eds. Depression and mania: comprehensive textbook. New York: Elsevier; 1988.

3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.

4. American Psychiatric Association. The practice of electroconvulsive therapy: recommendation for treatment, training and privileging. Washington, DC: American Psychiatric Association Press; 1990.

5. American Psychiatric Association. Practice Guidelines for Bipolar Disorder. Am J Psychiatry (in press).

6. American Psychiatric Association. Practice Guideline for Major Depressive Disorder in Adults. Am J Psychiatry 1993;150(suppl): 1–26.

7. Angst J. Clinical course of affective disorders. In: Mendlewicz J, Coppen A, van Pragg HM, eds. Depressive illness—biological psychopharmacological issues. Adv Biol Psychiatry. Vol 7. Basal: Karger; 1981:218–219.

8. Angst J, Bech P, Boyer P, Bruinvels R. Consensus conference on the methodology of clinical trials of antidepressants. Reports of the consensus committee. Pharmacopsychiatry 1988;22:3–7.

9. Baastrup PC, Paulsen JC, Schou M, Thomsen K, Amidsen A. Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent depressive disorders. Lancet 1970;2:326–330.

10. Belsher G, Costello CG. Relapse after recovery from unipolar depression: a critical review. Psychol Bull 1988;104:84–96.

11. Bjork K. The efficacy of zimelidine in preventing depressive episodes in recurrent major depressive disorders—a double-blind placebo-controlled study. Acta Psychiol Scand 1983;68(Suppl): 182–189.

12. Blackburn IM, Eunson KM, Bishop S. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. Affect Disord 1986; 10:67–75.

13. Bowden CL. What new data are available on lithium and anticonvulsants? Presented at the American Psychiatric Association Annual Meeting, San Francisco, May 1992.

14. Calabrese JR, Woyshville MJ, Kimmel SE, Rapport DJ. Mixed states and bipolar rapid cycling and their treatment with divalproex sodium. Psychiatric Ann 1993;23:70–78.

15. Coppen A, Ghose K, Montgomery S, Rao V, Bailey J, Jorgensen A. Continuation therapy with amitriptyline in depression. Br J Psychiatry 1978;133:28–33.

16. Coppen A, Noguera R, Bailey J, et al. Prophylactic lithium in affective disorders: controlled trial. Lancet 1971;2:326–330.

17. Depression Guideline Panel. Depression in primary care: Vol. 1. Treatment of major depression. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1993. AHCPR Publication No. 93-0551.

18. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1993;160:217–222.

19. Endicott J, Spitzer RL, Fleiss JL. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766–771.

20. Eric L. A prospective double-blind comparative multicentre study of paroxetine and placebo in preventing recurrent major depressive episodes. Biol Psychiatry 1991;29:2545.

21. Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Waternaux C. Episode sequence in bipolar disorder and response to lithium treatment. Am J Psychiatry 1991;148:1237–1239.

22. Fieve RR, Kumbaraci T, Dunner DL. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. Am J Psychiatry 1976;133:925–930.

23. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093–1099.

24. Frank E, Kupfer DJ, Perel JM, et al. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Dis 1993;27:139–145.

25. Frank E, Prien R, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry 1991;48:851–855.

26. Gelenberg AJ, Kane JM, Keller MB. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989;321:1489–1493.

27. Georgotis A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 1989;46:783–786.

28. Glen AIM, Johnson AL, Shepherd M. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized double-blind controlled trial. Psychol Med 1984;14:37–50.

29. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press; 1990.

30. Harrison W, Rabkin J, Stewart JW, et al. Phenelzine for chronic depression: a study of continuation treatment. J Clin Psychiatry 1986;47:346–349.

31. Haykal RF, Akiskal HS. Bupropion as a promising approach to rapid cycling bipolar II patients. J Clin Psychiatry 1990;51:450–455.

32. Hellerstein DJ, Yanowitch P, Rosenthal J, et al. A randomized double-blind study of fluoxetine versus placebo in treatment of dysthymia. Am J Psychiatry 1993;150:1169–1175.

33. Hollen SD, Evans MD, DeRubein RJ. Cognitive medication of relapse prevention following treatment for depression: implications of differential risk. In: Ingram RE, ed. Psychological aspects of depression. New York: Plenum Press; 1990:117–136.

34. Jamison KR. Psychotherapy. In: Goodwin FK, Jamison KR, eds. Manic-depressive illness. New York: Oxford University Press; 1990:725–745.

35. Jarrett RB, Ramanan J, Eaves GG, Kobes R, Basco MR, Rush AJ. How prophylactic is cognitive therapy in treating depressed outpatients? Paper presented at The World Congress of Cognitive Therapy. Toronto; 1992.

36. Kane JM. The role of neuroleptics in manic-depressive illness. J Clin Psychiatry 1988;49(Suppl):12–14.

37. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzo JR, Novak DD, Howard A. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness. A prospective placebo-controlled comparison. Arch Gen Psychiatry 1982;39:1065–1069.

38. Keller MB. Diagnostic issues and clinical course of unipolar illness. In: Francis AJ, Hales RE, eds. Review of psychiatry. Vol. 7. Washington DC: American Psychiatry Press; 1988:188–212.

39. Keller MB, Lavori PW, Endicott J, Coryell W, Klerman GL. "Double-depression:" two-year follow-up. Am J Psychiatry 1983; 140:689–694.

40. Keller MB, Shapiro RW, Lavori PW, Wolfe N. Relapse in major affective disorders. Arch Gen Psychiatry 1982;39:911–915.

41. Kocsis JH, Francis AJ, Voss C, et al. Imipramine treatment for chronic depression. Arch Gen Psychiatry 1988;45:253–257.

42. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of manic-depressive cycle and changes caused by treatments. Pharmakopsychiatr Neuropsychopharmakol 1980;13:156–167.

43. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52(Suppl):28–34.

44. Kupfer DJ. Maintenance treatment in recurrent depression: current and future directions. The first William Sargant Lecture. Br J Psychiatry 1992;161:309–316.

45. Kupfer DJ, Frank E. The minimum length of treatment for recovery. In: Montgomery S, Rouillon F, eds. Long-term treatment of depression. New York: John Wiley; 1992:33–52.

46. Maj M. Clinical prediction of response to lithium prophylaxis in bipolar patients: a critical update. Lithium 1992;3:15–21.

47. Maj M, Veltro F, Pirozzi S, Lobrace S, Magliano L. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry 1992;149:795–800.

48. Mindham RHS, Howland C, Shepperd M. An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med 1973;3:5–17.

49. Montgomery SA, Dufour H, Brion S, et al. Prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988;153 (Suppl):69–76.

50. Nardi E, Capponi R, Costa DA, Magistris W, Ucha R, Versiani M. Moclobamide compared with imipramine in the treatment of chronic depression (Dysthymia DSM-III-R). A double-blind placebo controlled trial. Clin Neuropharmacol 1992;15(Suppl):148.

51. NIMH/NIH Consensus Development Conference. Mood disorders: prevention of recurrences. Am J Psychiatry 1985;142:469–472.

52. O'Connell RA, Mayo JA, Flatow L, Cuthbertson B, O'Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991;159:123–129.

53. Old Age Depression Interest Group (OADIG). How long should the elderly take antidepressants? A double-blind placebo-controlled study of continuation/prophylaxis therapy with diothepin. Br J Psychiatry 1993;162:175–182.

54. Post RM. Anticonvulsants and novel drugs. In: Paykel ES, ed. Handbook of affective disorders. London: Churchill Livingstone; 1992:387–417.

55. Post RM. Issues in the long-term management of bipolar affective illness. Psychiatric Ann 1993;23:86–92.

56. Post RM, Kramlinger KG, Altshuler IL, Ketter TA, Denicoff K. Treatment of rapid cycling bipolar illness. Psychopharmacol Bull 1990;26:37–47.

57. Prien RF. Long-term treatment of affective disorders. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press; 1987:1051–1058.

58. Prien RF. Maintenance therapy. In: Paykel E, ed. Handbook of affective disorders. London: Churchill Livingston; 1992:419–435.

59. Prien RF, Gelenberg AJ. Alternatives to lithium for preventive treatment of bipolar disorder. Am J Psychiatry 1989;840–848.

60. Prien RF, Klett J, Caffey EM. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study. Arch Gen Psychiatry 1973;29:420–425.

61. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986;143:18–23.

62. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group. Arch Gen Psychiatry 1984;41:1096–1104.

63. Prien RF, Potter WZ. NIMH workshop on treatment of bipolar disorder. Psychopharm Bull 1990;26:409–427.

64. Reynolds CF, Frank E, Perel J, et al. Combined pharmacotherapy and psychotherapy in the acute and continuation treatment of elderly patients with recurrent major depression: a preliminary report. Am J Psychiatry 1992;149:1687–1691.

65. Robinson DS, Lerfald SC, Bennett B, et al. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discussion study. Psychopharm Bull 1991;27:31–39.

66. Rouillon F. Unwanted effects of long-term treatment. In: Montgomery S, Rouillon F, eds. Long-term treatment of depression. New York: John Wiley; 1992:81–112.

67. Rouillon F, Serrurier D, Miller H, Gerard M. Prophylactic efficacy of maprotiline on unipolar depression relapse. J Clin Psychiatry 1991;52:423–431.

68. Sackeim H, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S. The impact of medication resistance and continuation pharmacotherapy on relapse following responses to electroconvulsive therapy in major depression. J Clin Psychopharm 1990;10:96–104.

69. Schou M. Lithium treatment of manic-depressive illness. A practical guide. Basal: Karger; 1989.

70. Shea MT, Elkin I, Imber SM, et al. Course of depressive symptoms over follow-up: findings from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Arch Gen Psychiatry 1992;49:782–787.

71. Small JG, Milstein V, Klapper MH, Kellams JJ, Sharply PH. Electroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry 1988;45:727–732.

72. Thase ME. Long-term treatments of recurrent depressive disorders. J Clin Psychiatry 1992;53(Suppl):32–44.

73. Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive therapy of depression: potential implication for longer courses of treatment. Am J Psychiatry 1992;149:1046–1052.

74. Van Bardeleben U, Holsboer F. Effect of age on the cortisol response to human corticotropin-releasing hormone in depressed patients pretreated with dexamethasone. Biol Psychiatry 1991;29: 1042–1050.

75. Vestergaard P. Treatment and prevention of mania: a Scandinavian perspective. Neuropsychopharmacology 1992;7:249–259.

76. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987; 144:1403–1411.

77. Weissman MM, Klerman GL, Paykel ES, Prusoff BA, Hanson B. Treatment effects on the social adjustment of depressed patients. Arch Gen Psychiatry 1974;30:771–778.

78. Wells KB, Burnam A, Rogers W, Hays R, Camp P. The course of depression in adult outpatients. Results from the Medical Outcomes study. Arch Gen Psychiatry 1992;49:788–801.

79. World Health Organization Mental Health Collaborating Centres. Pharmacotherapy of depressive disorders: a consensus statement. J Affect Dis 1989;17:197–198.

Back to Chapter